Volution Immuno Pharmaceuticals SA
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Jan 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 22, 2027The maintenance fee for Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) (US 11,730,792) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Jun 15, 2027The maintenance fee for Method of treating peripheral nerve disorders (US 9,211,312) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,522,171 | EV576 for use in the treatment of viral infections of the respiratory tract In force · From the USPTO record | In force | From the USPTO record | |
| US 9,211,312 | Method of treating peripheral nerve disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 11,052,129 | Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism In force · From the USPTO record | In force | From the USPTO record | |
| US 11,214,602 | Coversin Variants Lacking C5 Binding In force · High confidence | In force | High confidence | |
| US 11,730,792 | Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 5: 1 patent in force now held by others · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned · 18 no status recorded
Showing 1 to 10 of 21, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/813,382 | Coversin for use in the treatment of rheumatic diseases | Aug 23, 2024 | Pending |
| 18/332,191 | Jun 9, 2023 | No status recorded | |
| 17/569,374 | Jan 5, 2022 | No status recorded | |
| 17/529,534 | Nov 18, 2021 | Abandoned | |
| 17/481,528 | Sep 22, 2021 | No status recorded | |
| 17/333,675 | May 28, 2021 | No status recorded | |
| 17/244,159 | Apr 29, 2021 | No status recorded | |
| 17/604,509 | Mar 4, 2020 | No status recorded | |
| 16/663,655 | Oct 25, 2019 | No status recorded | |
| 17/761,753 | Sep 27, 2019 | No status recorded |
10 of 21 applications shown.
Pro members see all 21 published applications.